Impact of upadacitinib or adalimumab as initial therapy on the achievement of 48-week treatment goals in patients with rheumatoid arthritis and inadequate response to methotrexate: Post hoc analysis of a phase 3 study

Impact of upadacitinib or adalimumab as initial therapy on the achievement of 48-week treatment goals in patients with rheumatoid arthritis and inadequate response to methotrexate: Post hoc analysis of a phase 3 study

Bibliographic Details
Main Authors: Mysler, E, Tanaka, Y, Kavanaugh, A, Aletaha, D, Taylor, PC, Song, IH, Shaw, T, Song, Y, Demasi, R, Ali, M, Fleischmann, R
Format: Conference item
Language:English
Published: BMJ Publishing Group 2021

Similar Items